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SUMMARY: The rejection of allotransplantation of epigastric microsurgical flaps and the effect of immunosuppression have been studied in 58
rats. Three sets of experiments were planned: (1) Wistar Furth isogenic donors and receptors (control set); (2) Brown Norway donors and Wistar Furth
receptors (rejection set); and (3) Brown Norway donors and Wistar Furth immunosuppressed receptors (cyclosporin A set). Cyclosporin A (10 mg/kg/d)
treated rats had a transplantation survival rate of up to 30 days: 83.3% among isogenic animals and 60% among allogeneic. There was 100% rejection by
the 9th day after the transplantation in allogeneic non-immunosuppressed rats. Biopsies embedded with historesin were taken from the flap and normal
contralateral skin (used as control) on the 3rd, 7th, 15th, and 30th days after the surgery. A quantitative study of infiltrating lymphocytes in the flaps, with
and without cyclosporin A, was done by evaluating the local inflammatory infiltrate. A significant increase in the number of lymphocytes among the
rejection and immunosuppressed groups was seen, as compared to the isogenic set. Local lymphocytosis in allogeneic non-immunosuppressed
transplantations reached its highest level on the 3rd day after surgery, before gross findings of rejection, which could only be seen by naked eye on the 5th
or 6th day. Therefore, we conclude that cyclosporin A is effective in preserving allogenic transplantation in rats. Biopsies of transplanted areas may
contribute to earlier diagnosis of the need for immunosuppressive therapy.
DESCRIPTORS:  Allotransplantation.   Cyclosporin A.
Organs and tissue transplantations
have always been one of the alterna-
tives suggested for the correction of
congenital acquired diseases16,30. How-
ever, tissues coming from autogenous
donor areas are relatively scarce.
Thus, there are clinical circum-
stances in which it would be desirable
to obtain tissues from donors (alive or
dead), as in very large burned areas1,7,8,
complex oncologic or traumatic tissue
loss, and limb reconstruction due to
trauma or aplasia11,32.
The improvement of skin graft sur-
vival with the use of cyclosporin A has
already been proved1,2,12,15,19. However,
attempts at achieving full integration of
skin grafts have not always been suc-
cessful1,9,17,21,23,34.
The use of immunosuppressing
drugs, usually accompanied by the
concurrent adverse side effects, has
fewer restrictions with organ transplan-
tations that are essential to the patient’s
survival. Limb and tissue transplanta-
tions, however, have more restraints20.
Therefore, allogeneic transplantations
of tissues and limbs27, despite their
technical feasibility, have not been
done in humans, and research has been
limited32.
In order to contribute to the study
of rejection of cutaneous allotrans-
plantations with and without the use of
cyclosporin A, we developed an experi-
mental model. Survival indexes and
lymphocyte quantitative studies were
performed.
MATERIAL  AND  METHOD
Fifty-eight epigastric flap microsur-
gical cutaneous allotransplantations
were performed. Three sets of experi-
ments were designed as follows:
– isogenic I (transplantation: Wistar
Furth as donors and receptors),
used as controls for the surgery ef-
fects;
– rejection R (allogenic transplanta-
tion: Wistar Furth receptors and
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Brown Norway donors), used to
study rejection;
– cyclosporin Ci (allogenic transplan-
tation with cyclosporin A treatment,
10 mg/kg/day intramuscular, Wistar
Furth receptors and Brown Norway
donors).
Both the donor and the receptor
were anesthetized with intraperitoneal
sodium pentobarbital 30 mg/kg). A
flap from the right lower abdominal
skin of each animal was obtained, ac-
cording to the technique.
A detailed description of gross
changes of the skin was recorded dur-
ing the 30 days following surgery. On
the third day after surgery, a micro-
scopic review of the anastomoses was
performed.
Biopsy specimens of the flap of the
contralateral skin (control) were ob-
tained from groups I and Ci on the 3rd,
7th, 15th, and 30th days after the surgery,
and from R group on the 3rd and 7th
postoperative days.
The specimens were prepared in
methacrylate historesin and stained
with toluidine blue, and are labelled as
follows:
ICo = control skin from the isogenic
group;
IT = isogenic group transplantation;
RCo = control skin from the rejection
group;
RT = rejection group transplantation;
CiCo = control skin from the
cyclosporin group;
CiT = cyclosporin group transplanta-
tion.
The postoperative day when the bi-
opsies were taken was added to the
code.
A double-blind study was per-
formed for lymphocyte quantitation in
the tissue. Lymphocyte quantitation
was performed through comparison of
means obtained in 18 fields. A grati-
cule adapted to the ocular (10x) with
50 randomly distributed lines was used,
and lymphocytes that were intersected
by the lines were counted. Due to the
great individual variations, a non-para-
metric statistical analysis was per-
formed with a Mann-Whitney-
Wilcoxon test37.  Statistical significance
was declared at p < 0.05.
RESULTS
Among the 58 animals that under-
went transplantation, 45 (77.6%) pre-
sented pervious anastomoses when
evaluated on the 3rd postoperative day.
Thirteen animals (22.4%) presented
thrombosis in artery, vein, or both near
the anastomoses, and therefore these
individuals were excluded from the
study.
Figure 1 - Illustration of epigastric flap: a - dono rat; b - receptor rat (dissected flap, preserved panniculus adiposus, vascular pediculous).
ba
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Figure 2 - Epigastric flap without rejection.
Table 1 - Analysis of microsurgic cutaneous transplantations survival in the
individuals within 30 days
Group NEC % NEC N NEC % N NEC
I 2/12 16.7 10/12 83.3
R 8/8 100.0 0/8 0
Ci 4/10 40.0 6/10 60.0
NEC = necrosis; N NEC = non necrosis; R = rejection; I = isogenic; Ci = cyclosporin A.
Figure 3 - Epigastric flap with rejection.
Among the 45 remaining rats, 30
survived to the end of the 30 day fol-
low-up period (12 from I, 8 from R and
10 from Ci group) (Table 1).
Daily microscopic analysis of the
flaps from I group showed moderate
edema, although color and hair devel-
opment remained similar to the adja-
cent skin area that had not undergone
surgery, other than local moderate
edema.
On the 1st and 2nd postoperative
days, Group R transplantations re-
sembled those of group I. Subse-
quently, local edema was much more
intense, and on the 4th or 5th day, hy-
peremia and local signs of tissue in-
volvement were evident, which
evolved from local ulceration and ne-
crosis to full necrosis between the 6th
and 9th days.
Among the 10 rats from the Ci
group, 60% of the flaps survived. Four
(40%) presented total necrosis at dif-
ferent times, observed on the 10th, 18th,
19th, and 24th postoperative days (Table
1). These animals showed an intense
early edema after surgery (3rd and 4th
days after surgery).
Gross examination of rats with 30-
day graft survival showed significant
differences between the three studies
sets, group I= 83,3%, group R = 0 and
group Ci = 60%.
Figures 2 and 3 are examples of the
features observed in the presence and
absence of rejection. Microscopic find-
ings are shown on Figs. 4 and 5.
There was a significant difference
in the histologic analysis of normal
skin and flap biopsies in all postopera-
tive days for groups R and Ci, and only
on the 15th day for I group. Lympho-
cytes in control skin among the 3
groups were scarce or absent in all
studied postoperative days.
We have compared counting of
lymphocytes among the different
groups for each studied postoperative
day. There were statistically significant
differences between of groups I and R
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on the 3rd postoperative day (Table 2),
and between the controls of I and Ci
groups on the 7th day (Table 3).
DISCUSSION
The feasibility of a future use of
allogeneic 60% tissue and limb trans-
plantations in reconstructive plastic
surgery11,14 justifies the development of
an experimental model for the system-
atic study of skin rejection.
A 77.6% vascular permeability was
obtained—a satisfactory rate, accord-
ing to the literature, in which 75 to
90% permeability has been
seen26,28,29,33.
The isogenic flap survival rate,
83.3%, was considered the basal line
for evaluation of the other sets of ex-
periments.
Mortality, although high (33.3%),
occurred in different postoperative
phases before we observed any gross
sign of rejection. Therefore, we were
able to evaluate transplantation for 30
days among the remaining 30 animals
without having to consider mortality as
a variant for the rejection factor.
In group R, flap loss occurred in
100% of the cases after 6 to 8 days, a
rate which is significantly different from
group I (Table 1). Gross findings for
group R clearly characterized a rejection
delay occurring according to the re-
ported literature22,31. However, rejection
occurred earlier than the ones observed
in organ transplantations, such as
heart4,13,18, kidney25,35,36, and small bowel
rejection in rats24. Similarly in the Ci
group, rejection occurred earlier than
for other tissues and organs, even with
the use of cyclosporin A22. A higher skin
antigenicity may be the reason why
flaps are rejected earlier than other tis-
sues, although the mechanism is not yet
fully understood5,6,10.
A 30-day follow-up survival was
observed in six flaps from Ci Group.
Four flap losses occurred on the 10th,
Table 2 - Lymphocyte counting: probality values Mann-Witney-Wilcoxem’s non
parametric test in the comparison of groups I, R and Ci on the 3rd postoperative
day.
Group and POday IT-3 CiTY-3
Postoperative day Isogenic set transplantation
CiT 0.199 -
RT-3 0.013* 0.143
(-) = comparison not performed
* significant values when p£0.05
CiT = cyclosporin set transplantation
RT = rejection set transplantation
Figure 4 - Histologic slide, with no inflammatory infiltrate, stained with toluidin blue, in the absence
of rejection.
Figure 5 - Histologic slide, with intense inflammatory infiltrate, stained with toluidin blue, in the
presence of rejection.
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17th, 18th, and 23rd postoperative days.
Therefore cyclosporin A was effective,
increasing survival rates of cutaneous
allogeneic transplantations.
Third day post-op biopsy lympho-
cyte counts had significant differences
between the allogenic non-treated
transplantation group (R) and isogenic
transplantation group (I) (Table 2).
Comparison between gross rejec-
tion findings and lymphocytic infiltra-
tion showed that lymphocyte infiltra-
tion precedes gross signs of necrosis.
The lymphocyte infiltration occurred
on the 3rd day post operative, whereas
symptoms of gross rejection were first
seen on the 6th post-operative day.
Therefore, as reported in the literature,
biopsy specimens must be taken and
examined for early signs of rejection in
order to prevent full necrosis of the
transplanted tissue.
In group Ci, there was a significant
difference in lymphocytes counted be-
tween transplanted and control sets.
Thus, it was observed that even though
cyclosporin A had a satisfactory action
on rejection control, its use did not result
in a decrease in the number of “in situ”
lymphocytes with the method used.
Based on what was found, the au-
thors continued researching immuno-
histochemical methods with mono-
clonal antibodies3,6,22 to identify the “in
situ” lymphocytes found in this experi-
mental model.
CONCLUSION
1) The rate of survival of epigastric
flap used as microsurgical cutaneous
transplantation to isogenic Wistar Furth
rats was 83.3% up to 30 days, confirm-
ing the efficacy of the adopted experi-
mental model.
2) In our experiments, when flaps
of Brown-Norway rats are transplanted
to Wistar-Furth receptors, a 100% re-
jection rate in non-immunosuppressed
transplantation occurs before the 9th
postoperative day.
3) Cyclosporin A immunosuppres-
sion (10 mg/kg/d) increased the allo-
geneic transplantation success up to 30
days post-operation.
4) Non-immunosuppressed allot-
ransplantation shows a significant in-
crease of infiltrating lymphocytes on
the 3rd day as compared to isogenic
transplantation. Symptoms of gross re-
jection findings are preceded by lym-
phocytic infiltration.
5) Despite the use of cyclosporin A,
an increased rate in the lymphocytic
infiltration was seen, as compared to
the control isogenic transplantation
group. Therefore, it may be assumed
that cyclosporin A induces rejection
delay, blocking the cytotoxic cell effect
or humoral immune reaction, even
though cell migration does occur.
6) The use of plastic embedded tis-
sue enables a better characterization of
the histological findings of rejection.
Further studies with immunohis-
tochemical cell sorting are ongoing in
our laboratories to enhance our knowl-
edge in this field.
Table 3 - Lymphocyte counting: probality values Mann-Witney-Wilcoxem’s non
parametric test in the comparison of groups I, R and Ci on the 7th postoperative
day.
Group and POday ICo-7 CiCo-7
Postoperative day Isogenic set control Cyclosporin set control
CiCo-7 7.919 x 10-3 -
RCo-7 0.693* 0.476
(-) = comparison not performed
* significant values when p£0.05
Rco = rejection set control
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Os efeitos da rejeição e da
imunossupressão com ciclosporina A
em retalhos epigástricos utilizados
como transplantes cutâneos alógenos
microcirúrgicos, foram estudados em 58
ratos, distribuídos em três grupos:
Wistar-Furth isogênicos doadores e
receptores; e Brown-Norway
doadores e Wistar-Furth receptores,
imunossuprimidos com cicloporina
A(10mg/kg/dia). Biópsias dos retalhos
e da pele normal contralateral utilizadas
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como contrôle foram colhidas no
terceiro, sétimo, 15º e 30º dias pós
transplante. As biópsias foram
preparadas em historesina, e
coradas em azul de toluidina, para
avaliação do infiltrado inflamatório lo-
cal, permitindo estudo quantitativo dos
linfócitos infiltrantes nos retalhos. O
modelo revelou-se eficiente, obtendo-se
sobrevivência dos transplantes por 30
dias, de 83,3% entre animais isogênicos,
e de 60% nos alogênicos sob ação da
ciclosporina A. Em ratos alogênicos não
imunossuprimidos houve 100% de
rejeição dos retalhos, até o nono dia
pós-operatório. Nos transplantes desses
animais, verificou-se aumento signifi-
cativo do número de linfócitos
infiltrantes no terceiro dia, quando
comparados aos ratos isogênicos. A
linfocitose observada antecedeu os
achados macroscópicos da rejeição,
verificados apenas no quinto ou sexto
dias.
 DESCRITORES: Transplante de
tecidos.    Ciclosporinas.
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